Skin News and Research

RSS

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Benefits and harms of screening infants for hyperbilirubinemia still unclear

According to a new recommendation from the U.S. Preventive Services Task Force, there is insufficient evidence to assess the balance of benefits and harms of screening infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. Hyperbilirubinemia is a condition marked by a high level of bilirubin in the blood, which is often apparent as yellow-colored skin and eyes (jaundice).

29 Sep 2009

Women feeling more positive about their genitals find it easier to orgasm

An Indiana University study published in the September issue of the International Journal of Sexual Health found that women who feel more positively about women's genitals find it easier to orgasm and are more likely to engage in sexual health promoting behaviors, such as having regular gynecological exams or performing vulvar self-examinations.

29 Sep 2009

Hygafem's hand sanitizing program launched at Morehouse College

Hygafem, Inc., the Georgia-based premier provider of touch-free workplace wellness technologies and services, has successfully launched its hand sanitizing program at Morehouse College in Atlanta, GA. Hygafem’s touch-free hand sanitizing program decreases the risk of spreading disease, ensures safe and healthy facilities, and boosts satisfaction for students and employees at Morehouse College.

29 Sep 2009

The mysterious origin of Merkel cells

A new study resolves a 130-year-old mystery over the developmental origin of specialized skin cells involved in touch sensation. The findings will appear in the October 5, 2009 issue of the Journal of Cell Biology (online September 28).

29 Sep 2009

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Photosynthesis can contribute to bacterial infiltration in fresh produce

Exposure to light and possibly photosynthesis itself could be helping disease-causing bacteria to be internalized by lettuce leaves, making them impervious to washing, according to research published in the October issue of the journal Applied and Environmental Microbiology.

29 Sep 2009

Hookworms can prevent asthma

A study conducted in Vietnam has added further weight to the view that parasitic gut worms, such as hookworm, could help in the prevention and treatment of asthma and other allergies.

29 Sep 2009

Heparin-induced skin lesions may indicate platelets deficit

Heparin, a commonly used anticoagulant, can cause skin lesions, reports a study http://www.cmaj.ca/press/cmaj081729.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

Combined immunodeficiency results in severe health problems

Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. The disorder, called combined immunodeficiency, is characterized by a constellation of severe health problems, including persistent bacterial and viral skin infections, severe eczema, acute allergies and asthma, and cancer.

28 Sep 2009

An overview on nanoparticles

At SINTEF scientist both exploit the benefits of the nanotechnology and try to discover how tiny particles could behave hazardous in nature.

28 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

U.S. underfunds climate change health-related research

A recent commentary suggests that the U.S. should spend roughly $197 million more than it currently does to research the impact of climate change on public health.

28 Sep 2009

Universal bilirubin screening can reduce jaundice incidence in newborns

Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.

28 Sep 2009

Initial clinical results for Mpathy Medical's Omnisure sling released

Mpathy Medical, a rapidly growing medical device company which has developed and brought to market a range of less invasive surgical solutions used to restore pelvic health to women, released the initial clinical results for its newest product, Omnisure™, a novel full length sling for treatment of female stress urinary incontinence (SUI) at the American Urogynecologic Society’s (AUGS) Annual Meeting.

26 Sep 2009

Stem Cell Therapy International merges with Histostem

Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").

25 Sep 2009

Stelara approved by the FDA for treating psoriasis

The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis.

25 Sep 2009

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.

25 Sep 2009

Cynosure to market Smartlipo MPX LaserBodySculpting Workstation in Korea

Broadening the reach of two of its flagship aesthetic laser products into the Asia Pacific region, Cynosure, Inc. today announced that it has received approval to market the Smartlipo MPX(TM) LaserBodySculpting(SM) Workstation in Korea and the Affirm(TM) Anti-Aging Workstation in the People's Republic of China.

25 Sep 2009